Naringin protects rat lung against the doxorubicin-induced biochemical injury

Since the isolation of doxorubicin (DOX) in 1960s from Streptomyces peucetius it has emerged as one of the most effective anticancer drugs for the treatment of cancer.1,2 Doxorubicin has been used clinically since 1970s, for the treatments of several malignant tumours including myeloblastic leukemias, lymphomas, breast cancer, small cell lung cancer, ovarian cancer, childhood solid cancers and soft tissue sarcomas.3‒5 The doxorubicin also finds its utility in the treatment of liver cancers.6 Recent phase I clinical trial has reemphasized the application of doxorubicin in conjunction with lurbinectedin (PM01183) as a useful paradigm in the treatment of patients presenting with small cell lung cancer.7